Work

Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2017-ct154

Authors: Christophe Meille, Nelson Guerreiro, Astrid Jullion, Sebastian Bauer, Manik Chatterjee, Filip de Vos, Chia-Chi Lin, Cristina Suárez Rodríguez, David Tai, Philippe Cassier, Noboru Yamamoto, Vincent A. de Weger, Matthieu Klopfenstein, Luisa Mariconti, Emil T. Kuriakose, David M. Hyman

Institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research, University of Duisburg-Essen, Universitätsklinikum Würzburg, University Medical Center Utrecht, National Taiwan University Hospital, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, National Cancer Centre Singapore, Centre Léon Bérard, National Cancer Centre Japan, The Netherlands Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2740199303

Cites:

Cited by: 7

Related to: 10